Changeflow GovPing Pharma & Drug Safety Method for Isolating Dopamine Neurons and Pharm...
Routine Rule Added Final

Method for Isolating Dopamine Neurons and Pharmaceutical Composition for Parkinson's Disease

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The EPO granted Patent EP3591039A1 to S-BIOMEDICS covering a method for isolating dopamine neurons and a pharmaceutical composition containing those neurons for treating Parkinson's disease. The patent, with inventors KIM Dong-Wook, YOO Jeong-Eun, LEE Dongjin, PARK Sanghyun, KIM Jongwan, and CHO Myung Soo, designates 44 European states. The invention is classified under IPC categories for cell culture (C12N 5/0793), CNS-active pharmaceutical compositions (A61K 35/30), and anti-Parkinson agents (A61P 25/16).

What changed

The EPO published EP3591039A1, granting S-BIOMEDICS exclusive rights to a method for isolating dopamine neurons and a pharmaceutical composition containing those isolated neurons for treating Parkinson's disease. The patent covers cell culture techniques (C12N 5/0793), CNS pharmaceutical compositions (A61K 35/30), and anti-Parkinson therapeutic applications (A61P 25/16) across 44 designated European contracting states.

Pharmaceutical and biotechnology companies developing cell-based Parkinson's therapies in Europe must account for this patent when designing research programs or commercial products. Competitors may need to pursue licensing arrangements with S-BIOMEDICS or develop non-infringing alternative methods. The patent provides 20-year protection from the filing date, with national phase deadlines varying by designated state.

What to do next

  1. Monitor for national phase entry deadlines in designated states
  2. Evaluate freedom-to-operate implications in EU markets
  3. Review licensing opportunities from S-BIOMEDICS

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

METHOD FOR ISOLATING DOPAMINE NEURONS AND PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE, CONTAINING DOPAMINE NEURONS ISOLATED USING SAME

Publication EP3591039A1 Kind: A1 Apr 01, 2026

Applicants

S-BIOMEDICS

Inventors

KIM, Dong-Wook, YOO, Jeong-Eun, LEE, Dongjin, PARK, Sanghyun, KIM, Jongwan, CHO, Myung Soo

IPC Classifications

C12N 5/0793 20100101AFI20200505BHEP A61K 35/30 20150101ALI20200505BHEP A61P 25/16 20060101ALI20200505BHEP C12N 5/00 20060101ALI20200505BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

IPC C12N 5/0793 IPC A61K 35/30 IPC A61P 25/16

Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3591039A1

Who this affects

Applies to
Pharmaceutical companies Biotech companies Investors
Industry sector
3254.1 Biotechnology
Activity scope
Patent granting Biotech IP registration CNS drug development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.